When we see a stock like this, we know how many damaged investors are out there.
Believe it or not, there’s some good news.
$RVNC investors you might be surprised, but you actually have a chance to recover your losses. Don’t miss it: https://11th.com/cases/revance-investor-settlement
The $17.25M Revance Therapeutics ($RVNC) settlement deadline is August 28, 2026.
If you purchased $RVNC shares between February 29, 2024 and December 6, 2024, you may be eligible.
The case alleges Revance misled investors about its business performance and merger discussions with Crown Laboratories before the stock fell sharply.
File your claim here: https://11th.com/cases/revance-investor-settlement
FAQ for $RVNC investors
Q:What is this settlement about?
A: Revance Therapeutics agreed to a $17M settlement over claims the company misled investors about its relationship with Teoxane and the delayed Crown tender offer.
Q: Who may qualify?
A: Investors who purchased or acquired $RVNC securities between Feb. 29, 2024 and Feb. 6, 2025.
Q: What’s the deadline?
A: The claim deadline is Aug. 28, 2026.
Q: What happened to the stock?
A: After disclosures about the Teoxane dispute and revised merger terms, Crown cut its offer price from $6.66/share to $3.10/share.
Q: Is my data safe with 11th Estate?
A: Security is our top priority. We use bank-level encryption and are SOC2-compliant. We only process the trade data required for the court audit, and your personal financial credentials stay private.
Q: What is the fee?
A: We work on a 20% success fee. We handle the math, the paperwork, and the filing. If you don't get a payout, you don't pay us a cent.
Q: How do I start?
A: Just click the link below to submit your claim through our secure portal. https://11th.com/cases/revance-investor-settlement
The $17 million Revance Therapeutics ($RVNC) deadline is August 28, 2026
If you bought shares between February 29, 2024, and February 6, 2025, you are likely eligible for the $17 million recovery fund.
This settlement resolves claims that Revance Therapeutics misled investors regarding its Teoxane dispute, delayed Crown tender offer, and related stock-price declines. The stock dropped following the disclosure, and now the company is paying back to impacted shareholders ($0.16 per share).
File your claim here: https://11th.com/cases/revance-investor-settlement
@asssfhhwwws Yes, absolutely! Securities class action settlements in the U.S. (like the Revance Therapeutics case) are based on the stock you purchased, not where you live. If you bought $RVNC shares on a U.S. exchange (NASDAQ) through your Korean brokerage account during the class period, you are eligible to claim your share of the settlement.
$RVNC — Updates for the Revance Therapeutics investor settlement
The settlement has just received preliminary approval, and you can already submit a claim to get payment.
📌 What happened?
Revance allegedly misled investors about the strength and sustainability of its Teoxane partnership and overall sales performance. The issue came to light when a breach notice, stricter contract terms, and financial concerns were disclosed, leading to a reduced acquisition offer and significant pressure on the company’s outlook.
❓ Who qualifies?
Buyers of $RVNC between February 29, 2024, and February 6, 2025, inclusive.
➡️ Apply now:
https://11th.com/cases/revance-investor-settlement
